Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole vs Amphotericin B/Itraconazole in HIV-negative Talaromycosis
NCT03827278Unknown
- Sponsor
- Guangxi Medical University
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Open-label trial of voriconazole in talaromycosis (2 arms), sponsored by Guangxi Medical University. Primary endpoints: 2-week all-cause mortality, 24-week all-cause mortality and 3 more. Status: unknown.
02
Drugs
voriconazole
03
Conditions
talaromycosis
Beyond the preview
Go deeper on NCT03827278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827278.